Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT04250337 Completed - Atopic Dermatitis Clinical Trials

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

ADhere
Start date: February 3, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.

NCT ID: NCT04239560 Completed - Radiodermatitis Clinical Trials

Preventive Effect of Boron-based Gel on Radiation Dermatitis

boron_gel
Start date: February 4, 2019
Phase: Phase 3
Study type: Interventional

Preventive Effect of Boron-based Gel on Radiation Dermatitis

NCT ID: NCT04239521 Completed - Asthma Clinical Trials

The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata

Start date: October 1, 2020
Phase:
Study type: Observational

This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and incidence of psychiatric co-morbidities in people with alopecia areata, (3) the prevalence and incidence of autoimmune and atopic conditions in people with alopecia areata, and (4) the incidence of common infections in people with alopecia areata.

NCT ID: NCT04238728 Completed - Clinical trials for Radiation Dermatitis

Silverlon to Reduce Radiation Dermatitis

Start date: August 31, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if a silver-nylon dressing (Silverlon®, Argentum Medical) is useful for the prevention or treatment of radiation dermatitis in patients receiving radiation therapy to the breast.

NCT ID: NCT04226092 Completed - Atopic Dermatitis Clinical Trials

Pre-SunBeam TEWL AUC

Start date: November 7, 2019
Phase: N/A
Study type: Interventional

Transepidermal Water Loss (TEWL) measurements are a valuable tool to determine the integrity of a person's skin barrier. In patients with skin conditions, like atopic dermatitis, skin barrier can be disrupted or weakened, leading to a more severe phenotype and disease characteristics. There are several commercially available TEWL measuring devices, including the Aquaflux AF200 and the GPSkin Barrier Pro. This study is a pilot study to determine if these two devices produce similar readings for TEWL/skin barrier on patients with and without atopic dematitis (AD). The research team would like to investigate whether these devices are comparable for initial TEWL readings as well as after several rounds of tape strips have been collected from the skin. Tape strips are small circular adhesives, much like tape, that remove the very outermost layers of skin cells. It will be important to know if both of these devices provide correlative values for TEWL once the outermost layers of the skin have been removed by tape stripping.

NCT ID: NCT04218877 Completed - Atopic Dermatitis Clinical Trials

The Factors Affecting Atopic Dermatitis in Children Age 1-3

Start date: March 10, 2020
Phase:
Study type: Observational

This study evaluates the influence of different triggers on atopic dermatitis manifestation in children under 3 years old.

NCT ID: NCT04218500 Completed - Clinical trials for Contact Dermatitis of Hands

The Effectiveness and Safety of Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Dermatitis

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

Occupational hand dermatitis (OHD) often occurs in intensive care unit (ICU) nurses, especially in individuals who are vulnerable due to irritant exposure e.g. hand rub alcohol and repeated hand washing activities. The use of moisturizer is one of the recommendations for skin care in OHD. Niacinamide which has anti-inflammatory effects and can improve the skin barrier function. Virgin coconut oil (VCO) is rich in lipids and lauric acid, and has an occlusive effect. Until now there are no guidelines and reference types of moisturizers for secondary prevention in DTAK.

NCT ID: NCT04212169 Completed - Atopic Dermatitis Clinical Trials

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

Start date: December 9, 2019
Phase: Phase 2
Study type: Interventional

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

NCT ID: NCT04210674 Completed - Diaper Rash Clinical Trials

Effects of Argan Spinosa Oil in the Treatment of Diaper Dermatitis in Infants and Toddlers

Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The study hypothesized that using the traditional medicinal product of Argan spinosa oil is more effective than conventional topical steroid ointment on the speed up of the healing process and alleviation the symptoms in children with diaper dermatitis after seven consecutive days of the treatment

NCT ID: NCT04195698 Completed - Atopic Dermatitis Clinical Trials

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Start date: January 15, 2020
Phase: Phase 3
Study type: Interventional

This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.